SCHEDULE 13G/A: Wasatch Advisors LP Boosts Stake in Esperion Therapeutics to 5.5%
Beneficial Ownership Report
Wasatch Advisors LP has filed an Amendment No. 5 to Schedule 13G, disclosing a 5.5% beneficial ownership stake in Esperion Therapeutics, Inc. as of March 31, 2025.
Summary
- Wasatch Advisors LP, a Delaware-based investment adviser, reported beneficial ownership of 10,931,257 shares of Esperion Therapeutics, Inc. common stock.
- This stake represents 5.5% of the total class of securities.
- Wasatch Advisors LP holds sole voting power over 9,839,213 shares and sole dispositive power over 10,931,257 shares.
- The filing is an Amendment No. 5 to their previously filed Schedule 13G, indicating an update to their ownership position.
Sentiment
Score: 6
Explanation: The filing indicates a significant beneficial ownership stake by an institutional investment adviser, which can be interpreted as a positive signal of confidence in the issuer. However, the document is purely a disclosure of ownership and does not contain operational or financial performance data, limiting a comprehensive sentiment assessment.
Positives
- The disclosure of a significant 5.5% beneficial ownership stake by Wasatch Advisors LP, a recognized investment adviser, may signal confidence in Esperion Therapeutics, Inc. from an institutional investor.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Esperion Therapeutics, Inc.'s future performance or operations.
Industry Context
This filing is a standard disclosure of institutional ownership and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical or biotechnology sector. It primarily reflects an investment decision by Wasatch Advisors LP.
Stakeholder Impact
- Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence and stability in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement (reporting period end) |
| 04/07/2025 | Date of filing of this statement |
Keywords
Esperion Therapeutics, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.